EP Patent

EP4727534A1 — Compositions comprising antineoplastons and methods of treating breast cancer

Assigned to Individual · Expires 2026-04-22 · 0y expired

What this patent protects

Disclosed herein are compositions comprising one or more antineoplastons and using those compositions in methods of treating breast cancer, prolonging the survival of a subject, and preventing and/or decreasing metastasis of breast cancer.

USPTO Abstract

Disclosed herein are compositions comprising one or more antineoplastons and using those compositions in methods of treating breast cancer, prolonging the survival of a subject, and preventing and/or decreasing metastasis of breast cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP4727534A1
Jurisdiction
EP
Classification
Expires
2026-04-22
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.